Do GPCRs constitute the target of 30% of newly approved drugs in Germany?
Saved in:
| Title: | Do GPCRs constitute the target of 30% of newly approved drugs in Germany? |
|---|---|
| Authors: | Schröer S; Hannover Medical School, Institute of Pharmacology, Carl-Neuberg-Str. 1, 30625, Hannover, Germany., Seifert R; Hannover Medical School, Institute of Pharmacology, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. Seifert.Roland@mh-hannover.de. |
| Source: | Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2026 Feb; Vol. 399 (4), pp. 5575-5604. Date of Electronic Publication: 2025 Nov 06. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0326264 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1912 (Electronic) Linking ISSN: 00281298 NLM ISO Abbreviation: Naunyn Schmiedebergs Arch Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1432-1912 |
|---|---|
| DOI: | 10.1007/s00210-025-04548-3 |
